ArticleBritish journal of haematology2015
MDM2 antagonist clinical response association with a gene expression signature in acute myeloid leukaemia.
Abstract readClinical Trial, Phase ILetter
In one paragraph
Article in British journal of haematology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Review
- FAM193A is a positive regulator of p53 activity.Cell reports · 2023Article
- p52-ZER6: a determinant of tumor cell sensitivity to MDM2-p53 binding inhibitors.Acta pharmacologica Sinica · 2023Article
- Targeting p53-MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials.Journal of hematology & oncology · 2022Review
- Pharmacogenomics characterization of the MDM2 inhibitor MI-773 reveals candidate tumours and predictive biomarkers.NPJ precision oncology · 2021Article
- miR-10a as a therapeutic target and predictive biomarker for MDM2 inhibition in acute myeloid leukemia.Leukemia · 2021Article
- The Role of p53 Signaling in Colorectal Cancer.Cancers · 2021Review
- MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388).OncoTargets and therapy · 2019Review
- Article
- Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition.Cancer research · 2018Article
- Pharmacological activation of wild-type p53 in the therapy of leukemia.Experimental hematology · 2016Review
- Acute myeloid leukemia patients' clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts.Haematologica · 2016Article
- Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.Molecular cancer therapeutics · 2016Article
- Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Hua ZhongPharmaceutical Sciences, Roche Pharmaceutical Research and Early Development, Roche Innovation Center New York, New York, NY, USA. hua.zhong@roche.com.
Gong ChenPharmaceutical Sciences, Roche Pharmaceutical Research and Early Development, Roche Innovation Center New York, New York, NY, USA.
Lori JukofskyTranslational Medicine Oncology, Roche Pharmaceutical Research and Early Development, Roche Innovation Center New York, New York, NY, USA.
David GehoTranslational Medicine Oncology, Roche Pharmaceutical Research and Early Development, Roche Innovation Center New York, New York, NY, USA.
Sung Won HanDivision of Biostatistics, Departments of Population Health, New York University School of Medicine, New York, NY, USA.
Fabian BirzelePharmaceutical Sciences, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Penzberg, Penzberg, Germany.
Sabine BaderPharmaceutical Sciences, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Penzberg, Penzberg, Germany.
Lucia HimmeleinPharmaceutical Sciences, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Penzberg, Penzberg, Germany.
James CaiInformatics, Roche Pharmaceutical Research and Early Development, Roche Innovation Center New York, New York, NY, USA.
Zayed AlbertynInformatics, Roche Pharmaceutical Research and Early Development, Roche Innovation Center New York, New York, NY, USA.
Mark RotheBiometrics, Product Development, Roche Innovation Center New York, New York, NY, USA.
Laurent EssiouxPharmaceutical Sciences, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Helmut BurtscherDiscovery Oncology, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Penzberg, Penzberg, Germany.
Steven A MiddletonTranslational Medicine Oncology, Roche Pharmaceutical Research and Early Development, Roche Innovation Center New York, New York, NY, USA.
Ruediger RuegerTranslational Medicine Oncology, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Penzberg, Penzberg, Germany.
Lin-Chi ChenTranslational Medicine Oncology, Roche Pharmaceutical Research and Early Development, Roche Innovation Center New York, New York, NY, USA.
Markus DanglDiscovery Oncology, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Penzberg, Penzberg, Germany.
Gwen NicholsTranslational Medicine Oncology, Roche Pharmaceutical Research and Early Development, Roche Innovation Center New York, New York, NY, USA.
William E PierceallTranslational Medicine Oncology, Roche Pharmaceutical Research and Early Development, Roche Innovation Center New York, New York, NY, USA.
Funding
Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ADRIANA HEGUY · 1985 to 2026
$83.1MNetwork based biosignature developmentR21GM110450 · NIGMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ZHONG, HUA JUDY · 2014 to 2014
$167kNCI NIH HHS P30 CA016087NIGMS NIH HHS R21 GM110450
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedCell Line, TumorFemaleGene Expression ProfilingGene Expression Regulation, LeukemicHumansImidazolinesLeukemia, Myeloid, AcuteMaleMiddle AgedProto-Oncogene Proteins c-mdm2ImidazolinesMDM2 protein, humanProto-Oncogene Proteins c-mdm2RG7112acute myeloid leukaemiadiagnostic algorithmgene expression signatureMDM2 antagonistTP53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.